Tag: March

Best business credit cards of March 2024

Whether you’re a start-up co-founder or a mom-and-pop store owner, you might benefit from having a business credit card. Business credit cards offer specific perks and advantages that are beneficial to small business owners.

Unlike personal credit cards, business credit cards enable you to separate your personal and business expenses, access larger lines of credit, and earn rewards in business-related spending categories. 

To determine the best business cards, we analyzed more than 40 cards and evaluated them based on factors like the annual fee, the rewards rate, the annual percentage rate (APR), the perks, and the insurance and protections. 

See our full methodology here.

The best business credit cards

The best business credit cards of March 2024

Note: Rates, fees, and account requirements are subject to change.

Best Flat Cash-Back Card: The American Express Blue Business Cash™ Card

American Express Blue Business Cash™ Card

Intro Bonus


$250 statement credit after you make $3,000 in purchases on your card in your first 3 months






0% intro offer 0% intro APR on purchases for 12 months from date of account opening (after that, the variable APR will be 18.49%–26.49% variable)
Annual fee $0
Regular APR 18.49%–26.49% variable


Why we like this card 

Of the business credit cards we ranked, the American Express Blue Business Cash™ Card had the highest flat cash-back rate: Cardholders earn 2% cash back on all eligible purchases on up to $50,000 per calendar year (then 1%). This means you can earn $1,000 cash back annually by spending up to the $50,000 cap. Plus, the card has a $0 annual fee, so you won’t have to pay to get these stellar cash back rates.

You can even earn a welcome

Read More ...

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13744458, or click on this Link and request a return call. The audio webcast can be accessed on the “Events and Presentations” page under the “Connect” tab of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need.

  • Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

  • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not U.S. Food and Drug Administration (FDA)-approved.

  • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and

Read More ...

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

Nemaura Medical, Inc

Nemaura Medical, Inc

Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and financial results for the fiscal year ended March 31, 2023.

Corporate Highlights:

 

 

  • Entered into a Registered Direct Offering and concurrent Private Placement for gross proceeds of approximately $8.4 million (before expenses).

  • Signed a preliminary agreement with Eversana to support a planned commercial launch of its Diabetes and Metabolic Health programs in the USA.

  • Announced initial patient data from UK NHS (National Health Service) Miboko Study that thus far demonstrated weight loss in 100% of participants, with further studies ongoing. The data is expected to support reimbursement applications and product marketing in various territories.

  • Continued to work with Benchmark Electronics Inc as a contract manufacturing partner (CMO) to facilitate future volume scale-up manufacture of the electronic transmitter at its FDA approved facility in Thailand, in anticipation of commercial-sales ramp-up.

  • Completed phased delivery of transmitters against the purchase order received from MSW in December 2021.

  • Received a provisional purchase order for 1.7 million sensors from its licensee TPMENA in anticipation of product registration in the KSA.

“We continue to build momentum on both manufacturing activities and consumer feedback through pilot trials, in preparation for scaling up commercial sales activities. The trials with the NHS in the UK have demonstrated the commercial potential for our sensors and digital health and wellbeing programs and has allowed us to undertake continuous refinements prior to commercial scale-up initiatives. Similarly, we believe working with world-class contract manufacturers and advancing our manufacture scale-up, and ensuring a well-managed supply chain through forward planning will support our planned commercial endeavours”, commented Dr Faz

Read More ...

Wall Street’s best week since March comes to quiet close

NEW YORK — Wall Street closed out its best week since March with a quiet finish on Friday, and stocks drifted to modest losses.

The S&P 500 fell 16.25 points, or 0.4%, to 4,409.59 after wobbling through the day. It still closed out a fifth straight winning week for its longest such streak since November 2021, and it remains close to its highest level since April 2022.

The Dow Jones Industrial Average slipped 108.94, or 0.3%, to 34,299.12, and the Nasdaq composite fell 93.25, or 0.7%, to 13,689.57.

Humana dropped 3.9% for one of the S&P 500’s sharpest losses after becoming the latest health insurer to warn about rising costs because of pent-up demand for medical services. Health insurance giant UnitedHealth issued a similar warning earlier in the week.

Treasury yields rose. The yield on the 10-year Treasury note rose to 3.76% from 3.72% late Thursday.

The yield on the two-year Treasury, which moves more on expectations for the Federal Reserve, rose to 4.72% from 4.65%.

The Fed held its benchmark interest rate steady at its meeting this week but warned that it could raise rates twice more this year. The central bank’s next meeting will run from July 25-26, and Wall Street is betting that it will raise rates. Traders are also mostly convinced that this will be the last increase of the year, according to data from CME Group.

Before taking its pause this week, the Fed had raised interest rates at 10 straight meetings since March 2022. Its goal has been to slow the economy to cool inflation but not so much that it causes a recession.

“The idea that the Fed is pausing and taking time to see what the cumulative effect is on the economy from a policy standpoint, is the right move for them,”

Read More ...

U.S. company activity accelerates in March – S&P International survey

WASHINGTON, March 24 (Reuters) – U.S. business enterprise activity attained steam in March as orders rebounded for the 1st time in 6 months, in accordance to a survey on Friday, which also suggested that inflation could go on to sluggish steadily.

S&P Global claimed its flash U.S. Composite PMI Output Index, which tracks the production and products and services sectors, increased to 53.3 this thirty day period. That was the greatest reading given that very last May and adopted a remaining reading of 50.1 in February.

It was the second straight month that the PMI remained previously mentioned 50, indicating growth in the personal sector. A evaluate of new orders gained by non-public businesses jumped to 51.2 from 48.5 in February. It was the 1st time since September that business in basic documented progress in new orders.

“March has so much witnessed an encouraging resurgence of financial progress,” mentioned Chris Williamson, main business enterprise economist at S&P World-wide Industry Intelligence.

Reuters Graphics Reuters Graphics

The increase in orders was concentrated in the expert services sector, with orders in manufacturing however weak, nevertheless off the prior months’ minimal levels. A new tightening in financial circumstances in the aftermath of the failure of two regional banking companies casts a shadow above the outlook for get expansion. There are fears that the ensuing tightening of lending specifications by banking institutions could make credit rating fewer accessible to households and corporations.

Federal Reserve Chair Jerome also alluded to this, telling reporters on Wednesday that “the situations of the last two weeks are probably to outcome in some tightening of credit score disorders for homes and firms, and therefore weigh on need on the labor sector and inflation.”

The Fed raised its benchmark right away interest charge by a quarter of a proportion level, but

Read More ...